- Report
- September 2026
- 279 Pages
Global
From €5318EUR$5,850USD£4,572GBP
- Report
- September 2026
- 383 Pages
Global
From €5318EUR$5,850USD£4,572GBP
- Report
- May 2026
- 350 Pages
Global
From €4499EUR$4,949USD£3,868GBP
- Report
- July 2026
- 150 Pages
Global
From €3409EUR$3,750USD£2,931GBP
- Report
- May 2026
- 150 Pages
Global
From €3409EUR$3,750USD£2,931GBP
- Report
- May 2026
- 138 Pages
Global
From €2726EUR$2,999USD£2,344GBP
€3635EUR$3,999USD£3,125GBP
- Report
- August 2026
- 148 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- April 2026
- 180 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- August 2026
- 108 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- August 2026
- 120 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- July 2026
- 115 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- July 2026
- 114 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- May 2026
- 156 Pages
Global
From €3590EUR$3,950USD£3,087GBP
- Report
- January 2026
- 140 Pages
Global
From €3590EUR$3,950USD£3,087GBP
- Report
- March 2026
- 198 Pages
Global
From €4409EUR$4,850USD£3,790GBP
- Report
- February 2026
- 181 Pages
Global
From €4409EUR$4,850USD£3,790GBP
- Report
- July 2026
- 160 Pages
Global
From €3018EUR$3,320USD£2,595GBP
€3772EUR$4,150USD£3,243GBP
- Report
- July 2026
- 160 Pages
Global
From €3018EUR$3,320USD£2,595GBP
€3772EUR$4,150USD£3,243GBP
- Report
- April 2026
- 160 Pages
Global
From €3018EUR$3,320USD£2,595GBP
€3772EUR$4,150USD£3,243GBP
- Report
- August 2026
- 160 Pages
Global
From €3018EUR$3,320USD£2,595GBP
€3772EUR$4,150USD£3,243GBP

The Antisense Oligonucleotide market is a segment of the biotechnology industry that focuses on the development of drugs that use short strands of nucleic acids to target and inhibit the expression of specific genes. These drugs are used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. Antisense oligonucleotides are designed to bind to a specific mRNA sequence, blocking the translation of the gene into a protein. This technology has the potential to revolutionize the treatment of many diseases, as it can be used to target specific genes without affecting other parts of the body.
The Antisense Oligonucleotide market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Arrowhead Pharmaceuticals. Other companies in the market include Regulus Therapeutics, Dicerna Pharmaceuticals, and Quark Pharmaceuticals. Show Less Read more